Recruitment and Eligibility of a Diverse Study Population in INTERCEPT-AD: A phase I trial of Aβ oligomer-targeting ACU193 in early Alzheimer&#39;s disease

ACU193 - Acumen Pharma

https://www.ctad-alzheimer.com/files/files/CTAD%20ABSTRACT%202023%20oct%2024_compressed.pdf

Robyn Moxon 1; Todd Feaster 1; Gopalan Sethuraman 1; Alyssa Carroll 1; Siew Tin Gan 1; Shane Ziemba 1; Kimber Price 1; Vladimir Skljarevski 1; Karen Sundell 1; Janice Hitchcock 1; Eric Siemers1

Jul 4, 2023